IL10 and COVID-19: Taken together, our data show that IFN-γ-licensed MSCs are capable of modulating the immune response triggered by the inflammatory milieu produced by lung cells exposed to NS antigens, reducing the levels of critical cytokines in COVID-19, such as IL-10 and IL-6.